The global topical drug delivery market is anticipated to grow at a considerable CAGR of 6.1% during the forecast period. The key factor contributing to the market growth includes the increasing approvals, grants, and clearance by government authorities and regulatory bodies for topical drugs. For instance,
Browse the full report description of “Topical Drug Delivery Market Size, Share & Trends Analysis Report by Product (Semi-Solid Formulations, Liquid Formulations, Solid Formulations, and Transdermal Products), by Route of Administration (Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Vaginal Drug Delivery, and Nasal Drug Delivery), and by Facility of Use (Home Care Settings, Hospitals & Clinics, Burn Centers, and Other Facilities) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/topical-drug-delivery-market
• In July 2022, Alembic Pharmaceuticals, (Aleor Dermaceuticals) received the US Food and Drug Administration (US FDA) approval for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel. This newly approved drug is for the topical treatment of actinic keratoses and now it is a reference listed drug product (RLD) Solaraze Topical Gel, 3%.
• In July 2022, Arcutis Biotherapeutics, Inc. received approval by the US FDA for its New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% that is used in the treatment of plaque psoriasis, including intertriginous areas. This newly approved drug offers rapid clearance of psoriasis plaques and reduces itching, and it is set to be available by mid of August 2022.
• In August 2020, LEO Pharma A/S, an investigational topical pan-Janus kinase (JAK)-inhibitor, a delgocitinib cream, has been granted Fast Track designation by the US FDA for the treatment of adults with moderate-to-severe chronic hand eczema (CHE).
• In June 2020, TDupixent (dupilumab) used for treating moderate-to-severe atopic dermatitis in adults has been approved by the National Medical Products Administration (NMPA) in China. It stated Dupixent as an overseas medicine and approval was based on positive data from the global LIBERTY AD clinical trial program and is medicine considered urgently needed in clinical practice.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Product
o By Route of Administration
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AbbVie Inc., Glenmark Pharmaceuticals Ltd., Merck KGaA, Novartis International AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Topical Drug Delivery Market Report Segment
By Product
• Semi-Solid Formulations
o Creams
o Ointments
o Lotions
o Gel
o Pastes
• Liquid Formulations
o Suspensions
o Solutions
• Solid Formulations
o Powders
o Suppositories
• Transdermal Products
o Transdermal Patches
o Transdermal Semi-Solids
By Route of Administration
By Facility of Use
Global Topical Drug Delivery Market Report by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/topical-drug-delivery-market